Clinical trial · Interventional
PTC Drug Sensitivity Detection to Guide Postoperative Adjuvant of Colorectal Cancer
Vitro 3D Drug Sensitivity Detection of Micro Tumor (PTC) to Guide Postoperative Adjuvant Treatment Strategy and Prognosis Judgment of Colorectal Cancer--Prospective Clinical Study
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The research objectives is to compare vitro 3D drug sensitivity test results of micro tumor (PTC) with the clinical outcomes of patients, evaluate the consistency between the test results of the technology platform and the clinical prognosis, and explore the decision-making value and guiding significance of this technology in assisting the precise treatment of colorectal cancer. The completion of this study will provide real-world data support for the clinical application of micro tumor (PTC) in vitro 3D drug sensitivity detection technology, and provide more valuable reference basis for realizing the individualization and accuracy of colorectal cancer treatment and improving the clinical benefit rate.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Colo-rectal Cancer | — | UNRESOLVED | — |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| adjuvant therapy based on 3D drug sensitivity test results of micro tumor (PTC) in vitro | Drug | — | UNRESOLVED |
Design
Arms and outcomes
Arms (2)
- type
- EXPERIMENTAL
- label
- experimental group
- description
- Select adjuvant chemotherapy scheme according to 3D drug sensitivity test results of micro tumor (PTC) in vitro
- interventionNames
- Drug: adjuvant therapy based on 3D drug sensitivity test results of micro tumor (PTC) in vitro
- type
- NO_INTERVENTION
- label
- control group
- description
- Formulate adjuvant chemotherapy strategy based on clinical experience
Primary outcomes (1)
- measure
- Follow-up and record DFS of patients
- timeFrame
- 3 years after enrollment
- description
- We follow-up the patients by outpatient/telephone/online message to find out their survival situation and record their Disease-free-survival time
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
- Maximum age
- 75 Years
Show eligibility criteria text
Inclusion Criteria: 1. Age 18 \~ 75 years old, regardless of gender 2. Patients with colorectal cancer diagnosed by histopathology or cytology 3. Colorectal cancer patients who need adjuvant therapy after radical surgery and have not received neoadjuvant therapy 4. Having at least one assessable tumor focus 5. ECoG physical condition score ≤ 2 points 6. Voluntarily participate and sign informed consent Exclusion Criteria: 1. Patients diagnosed with metastasis 2. Patients who cannot obtain tumor samples 3. Pregnant and lactating women 4. Patients with poor compliance 5. Patients with severe cardiovascular and cerebrovascular complications who cannot receive adjuvant treatment 6. Patients with other malignant tumors 7. Suffering from serious mental and nervous system diseases 8. The researchers believe that patients should not be selected for this study
References
Publications (0)
Data not yet available